SIC
XERS icon

SJS Investment Consulting’s Xeris Biopharma Holdings XERS Stock Holding History

SJS Investment Consulting’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33K Buy
294
+231
+367% +$1.48K ﹤0.01% 1712
2026
Q1 		$366 Buy
63
+44
+232% +$292 ﹤0.01% 1846
2025
Q4 		$150 Buy
+19
New +$150 ﹤0.01% 1877

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SJS Investment Consulting's XERS Position: Q2 2026 in Review

SJS Investment Consulting increased its Xeris Biopharma Holdings (XERS) stake by 367% in Q2 2026, buying an estimated $1.48K and bringing the position to 294 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

SJS Investment Consulting first reported a position in XERS in Q4 2025 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • SJS Investment Consulting held 294 shares of Xeris Biopharma Holdings worth $2.33K as of Q2 2026.
  • SJS Investment Consulting bought 231 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.48K.
  • Xeris Biopharma Holdings made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1712 holding.
  • SJS Investment Consulting first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.